Download Image
    
Share
  
Post
DFV890 for COVID-19
1 study with 142 patients
Hospital Icon Control
Hospital Icon DFV890 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 DFV890 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -3% Mortality -3% RCTs -3% Late -3% FavorsDFV890 Favorscontrol
Sep 14
2022
 Madurka et al., Infection, doi:10.1007/s15010-022-01904-w DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
3% higher mortality (p=1) and 1% worse recovery (p=0.95). RCT 143 hospitalized patients with COVID-19 pneumonia showing no significant difference in APACHE II scores with DFV890 (NLRP3 inhibitor).